Wuxi PharmaTech closing in on $3.3b take-private

The deal would be the second-largest privatisation of a US-listed Chinese company and could pave the way for a relisting in China or Hong Kong if completed.

Wuxi PharmaTech closing in on $3.3b take-private

A consortium led by founder Ge Li is only a step away from taking Wuxi PharmaTech private in a $3.3 billion deal after two proxy advisory firms recommended shareholders of the New York-listed pharmaceutical company vote for the privatisation proposal.

Glass Lewis and Institutional Shareholder Services both advised shareholders to approve the deal, Wuxi PharmaTech said in a statement Wednesday.

In the proposal tabled on April 29 the consortium offered...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES

  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...